Patent Prosecution Highway

Israeli Cannabis Technology Company BYND Cannasoft Enterprises Provides Update on International Patent Application Process for its Revolutionary EZ-G Device

Retrieved on: 
Thursday, November 3, 2022

BYND Cannasoft can now accelerate the examination of its present application in some jurisdictions, such as the US and Israel, as part of a PCT-PPH program .

Key Points: 
  • BYND Cannasoft can now accelerate the examination of its present application in some jurisdictions, such as the US and Israel, as part of a PCT-PPH program .
  • In September, BYND Cannasoft completed its acquisition of Zigi Carmel Initiatives & Investments Ltd., which holds the intellectual property for the patent-pending EZ-G device.
  • At that time, BYND Cannasoft announced plans to pursue the patent and establish a marketing and sales system for the EZ-G device based on B2B and B2C sales.
  • Since BYND Cannasoft purchased Zigi Carmel Initiatives & Investments, I have been committed to bringing the EZ-G device to market as quickly as possible.

Crowdworks registers its first US patent

Retrieved on: 
Monday, August 1, 2022

This technology of Crowdworks was recognized for its excellence and was quickly registered through the Patent Prosecution Highway (PPH) system.

Key Points: 
  • This technology of Crowdworks was recognized for its excellence and was quickly registered through the Patent Prosecution Highway (PPH) system.
  • A total of 50 domestic and foreign patent applications and registrations were completed last year alone, including 18 new domestic patent applications, 20 domestic registered patents, 11 new international patent applications and 5 international registered patents.
  • Crowdworks has 9 Japanese patent registrations and 5 applications, such as the pre-processing inspection method and the Autonomous driving training image extraction method.
  • Crowdworks is one of the leading AI training data annotation solution provider in Korea since 2017.

Japan Patent Office Launches "The JPO Key Features," Portal Site for Global IP Users

Retrieved on: 
Wednesday, January 26, 2022

The update has enhanced the content of the JPO website with information on designs, trademarks and appeals, in addition to patents.

Key Points: 
  • The update has enhanced the content of the JPO website with information on designs, trademarks and appeals, in addition to patents.
  • The update also covers helpful resources for global IP portfolio development.
  • Given the increasing number of international applications to the JPO, this content will help companies doing business in Japan, as well as elsewhere around the world.
  • The number of patent, design and trademark applications filed with the JPO from all over the world is on the increase.

Lutris Pharma Expands Intellectual Property Portfolio Surrounding its Novel B-Raf inhibitors Including Lead Asset LUT014

Retrieved on: 
Wednesday, December 8, 2021

TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that it has expanded the intellectual property (IP) surrounding its novel B-Raf inhibitors, including lead compound LUT014, a topically applied, novel B-Raf inhibitor for the treatment of cutaneous reactions caused by treatment with epidermal growth factor receptor (EGFR) inhibitors and/or PI3K inhibitors and treatment of radiation dermatitis (RD) caused by radiation therapy, in both the U.S. and internationally. Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.

Key Points: 
  • Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.
  • Additional non-U.S. applications have been accepted for expedited examination based on the allowed U.S. applications under the Patent Prosecution Highway program.
  • Lutris also has additional provisional patents for dosing and novel indications.
  • Additional information on the patent portfolio can be found on "Intellectual Property" section of the Lutris website at: www.lutris-pharma.com/intellectual-property .

Lutris Pharma Expands Intellectual Property Portfolio Surrounding its Novel B-Raf inhibitors Including Lead Asset LUT014

Retrieved on: 
Wednesday, December 8, 2021

TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that it has expanded the intellectual property (IP) surrounding its novel B-Raf inhibitors, including lead compound LUT014, a topically applied, novel B-Raf inhibitor for the treatment of cutaneous reactions caused by treatment with epidermal growth factor receptor (EGFR) inhibitors and/or PI3K inhibitors and treatment of radiation dermatitis (RD) caused by radiation therapy, in both the U.S. and internationally. Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.

Key Points: 
  • Within its patent portfolio, Lutris currently has a total of 13 issued national patents covering eight countries, as well as 17 patents pending.
  • Additional non-U.S. applications have been accepted for expedited examination based on the allowed U.S. applications under the Patent Prosecution Highway program.
  • Lutris also has additional provisional patents for dosing and novel indications.
  • Additional information on the patent portfolio can be found on "Intellectual Property" section of the Lutris website at: www.lutris-pharma.com/intellectual-property .

DeepTarget Granted Patent for Groundbreaking Digital Experience Platform and 3D Storyteller Technology

Retrieved on: 
Tuesday, October 26, 2021

11,157,966 for its Digital Experience Platform (DXP) including 3D StoryTeller , related to uniquely engaging digital banking consumers at scale.

Key Points: 
  • 11,157,966 for its Digital Experience Platform (DXP) including 3D StoryTeller , related to uniquely engaging digital banking consumers at scale.
  • When DeepTarget DXP is combined with the transformative, socially-inspired 3D Storyteller, marketers turn raw data into engaging and personalized user experiences in real time.
  • This patent strengthens DeepTargets position at the forefront of digital marketing innovation, said Preetha Pulusani, CEO of DeepTarget.
  • DeepTarget provides a single Digital Experience Platform for financial institutions to manage the complete engagement-to-results lifecycle across all digital channels, resulting in increased revenue, loyalty and trust and decreased costs.